Cytek Biosciences, Inc. (CTKB)

Over the past six months, Cytek Biosciences' stock price has been impacted by several events. In November 2025, Cytek was included on TIME's 2026 list of America's Growth Leaders, and Piper Sandler maintained an "Overweight" recommendation. In February 2026, the company reported its Fourth Quarter and Full Year 2025 financial results, leading to a stock price increase. In March 2026, Cytek celebrated one year of operations at its Singapore facility. In April 2026, Millennium Group reported holding 6.64 million shares in CTKB. In May 2026, Cytek reported its First Quarter 2026 financial results, missing EPS and revenue estimates, which led to a stock price decrease. Despite the earnings miss, recurring revenue from services and reagents showed strong growth, and management reaffirmed its full-year 2026 revenue guidance.

Cytek Biosciences' business experiences some level of demand seasonality. The company's annual report mentions "seasonal demands" as a factor that can influence customer demand for its products. Management indicated expectations for a "typical seasonal increase in subsequent quarters" for adjusted gross margin and projected that adjusted EBITDA would increase in later quarters due to "normal seasonal revenue patterns." This suggests that the first quarter may typically be a softer period, with demand and financial performance generally improving throughout the rest of the year.

Cytek Biosciences, Inc. (CTKB) is a cell analysis solutions company specializing in advanced tools for high-parameter cell analysis, headquartered in Fremont, California. The company operates within the analytical laboratory instrument manufacturing industry, focusing on flow cytometry and spectral cell analysis. Cytek's core business revolves around its patented Full Spectrum Profiling™ (FSP®) technology, which enables high-resolution analysis of single cells. Its major products include FSP instruments like the Cytek Aurora™ series, Enhanced Small Particle™ (ESP™) detection technology, the Cytek Orion™ reagent cocktail preparation system, and flow cytometers and imaging products sold under the Amnis® and Guava® brands. Cytek also provides reagents, software, and services, offering integrated cell analysis solutions. While most products are for research use only, some are approved for clinical use in China and the European Union.

Cytek Biosciences has a global presence with offices and distribution channels worldwide, including its Fremont headquarters. The company has direct sales and support in North America, Europe, China, and Asia-Pacific, and uses distributors in Europe, Latin America, and the Middle East. In October 2025, Cytek expanded its European headquarters in Amsterdam. The company also has manufacturing operations in the U.S., China, and Singapore, with a new facility opened in Singapore in early 2025.

Cytek Biosciences has received positive recognition, including its inclusion on TIME's 2026 list of America's Growth Leaders. The company's FSP systems have been cited in over 3,200 peer-reviewed publications, and its Cytek Cloud bioinformatics platform has strong customer engagement. Operational expansions, such as the Singapore facility anniversary and the expanded European headquarters, also contribute positively to its brand image. However, the company's reputation among investors may have been affected by a broader industry trend in 2024, which saw a decline in life science tools stocks due to a cyclical decrease in demand for capital equipment in certain markets. More recently, the Q1 2026 earnings report, which showed an EPS and revenue miss, led to a drop in stock price and could impact investor sentiment in the short term. Geopolitical events, such as the conflict in the Middle East, also negatively impacted EMEA revenue in Q1 2026, which could indirectly affect the company's perception in those regions.

Institutional investors hold a significant majority of Cytek Biosciences' shares. As of 2025, institutional investors collectively held 60.91% of the company's shares, and this figure was 52% in January 2026 and 63.81% in May 2026. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., Topline Capital Management, LLC, Hillhouse Capital Advisors, Ltd., Boston Partners, Millennium Management Llc, State Street Corp, Geode Capital Management, Llc, Dimensional Fund Advisors Lp, Brown Capital Management Llc and RA Capital Management LP. Key individual owners and insiders include the company's co-founders Dr. Wenbin Jiang (CEO and Chairman) and Dr. Ming Yan (CTO and Board Member).